Anavex Short Report

Abstract

Anavex Life Sciences (NASDAQ: $AVXL) is a pre-revenue biopharmaceutacal company pursuing EMA approval for their lead drug candidate, blarcamesine, which is a small-molecule Sigma-1 receptor agonist, for the treatment of early Alzheimer’s disease (AD). Blarcamesine has limited efficacy, significant treatment-emergent adverse events, a failed phase IIb/III trial, and a developer with a track record of deceit, spin and manipulation. This drug will not receive EMA approval. After a negative recommendation against approval from the CHMP, Anavex stock will likely see a 50+% decline in its share price.